Researchers are increasingly interested in cannabigerol (CBG), a non‑psychoactive cannabinoid found in the cannabis plant, because it interacts with many biological systems in the body that influence health and wellness. This comprehensive review summarizes what scientists currently know about CBG’s molecular mechanisms—how it works at the cellular level—and its therapeutic potential across a range of conditions based on laboratory, animal, and early clinical studies.

The review highlights that CBG interacts with the endocannabinoid system, which plays a role in regulating mood, pain, inflammation, appetite, and immune responses. Beyond that, CBG also affects other cell signaling pathways, including those involved in inflammation, oxidative stress, nerve function, and metabolic processes. In preclinical research, CBG has shown promise for reducing inflammation, supporting neuronal health, combatting bacterial infections, promoting appetite, and modulating immune activity. These effects are thought to arise from CBG’s ability to engage multiple receptors and protein targets beyond the traditional cannabinoid receptors.

While many findings are still preliminary and mostly come from laboratory and animal research, the review concludes that CBG’s broad range of biological activity makes it an interesting candidate for further study in human health. Well‑controlled clinical trials are needed to clarify dosing, safety, and effectiveness for specific conditions, but the current evidence provides a strong scientific foundation for future investigations into how CBG may support overall wellness.

Source

Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential (November 2024) Available through the National Library of Medicine (NIH):
https://pmc.ncbi.nlm.nih.gov/articles/PMC11597810/